Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jul 5;5(7):e003531. doi: 10.1161/JAHA.116.003531

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Reduction of infarct size by zofenopril pretreatment in a swine model of myocardial ischemia/reperfusion (I/R). A, Representative mid‐ventricular heart slices from placebo‐ and zofenopril‐treated animals. Area‐at‐risk (AAR) per left ventricle (LV) and infarct (INF) per AAR and LV were determined with a dual stain technique. There was no difference in AAR/LV between placebo‐ and zofenopril‐treated groups. B, Zofenopril pretreatment significantly reduced INF/AAR and INF/LV compared with placebo. C and D, Plasma levels of cTn‐I measured at time 0, 60 minutes of ischemia, and 15 minutes and 2, 4, 6, 24, and 48 hours of reperfusion and cumulative release of cTn‐I. Zofenopril reduced cTn‐I release during reperfusion with no significant extent. Results are expressed as mean±SEM. Number in the circle inside the bar denotes the number of animals used per group.